Artificial Intelligence for Screening of Multiple Corneal Diseases
Launched by TIANJIN EYE HOSPITAL · Jan 8, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new technology that uses artificial intelligence (AI) to help detect various corneal diseases. The researchers have developed a computer program that analyzes images of the front part of the eye, called anterior segment images, to identify potential issues with the cornea. The goal is to see how well this AI can accurately find these diseases compared to traditional methods.
To participate in this study, participants must have high-quality images taken by a special microscope called a slit lamp, which should clearly show key areas of the eye, including the sclera (the white part), pupil, and lens. If someone is interested in joining, they should have clear images that can help with diagnosis. The study is currently recruiting people of all ages and genders. Participants can expect to have their eye images assessed by the AI program and could contribute to improving how corneal diseases are diagnosed in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. The quality of slit-lamp images should clinical acceptable.
- • 2. More than 90% of the slit-lamp image area including three main regions (sclera, pupil, and lens) are easy to read and discriminate.
- Exclusion Criteria:
- • 1）Insufficient information for diagnosis.
About Tianjin Eye Hospital
Tianjin Eye Hospital is a leading medical institution specializing in ophthalmology, dedicated to advancing eye health through innovative research and clinical excellence. As a prominent clinical trial sponsor, the hospital is committed to conducting rigorous studies that explore new treatments and therapies for a variety of eye-related conditions. With state-of-the-art facilities and a team of experienced professionals, Tianjin Eye Hospital fosters collaboration with researchers and healthcare providers to enhance patient care and contribute to the global understanding of ocular health. Its focus on patient-centered research ensures that clinical trials are designed to prioritize safety, efficacy, and the well-being of participants.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tianjin, Tianjin, China
Patients applied
Trial Officials
Yan Wang, Prof
Study Chair
Tianjin Eye Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported